Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated complications. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.